At week 48 , although there was no significant difference in the mean reduction of serum HBV DNA from baseline between LdT + ADV group and LAM + ADV group ( -0.81 vs -0.47 log10 IU/mL , P = 0.167 ) , more patients in the LdT + ADV group had undetectable HBV DNA levels compared to those in the LAM + ADV group ( 30.2 % vs 11.5 % , P = 0.019 ) .